Bli medlem
Bli medlem

Du är här

2015-11-09

Oncology Venture: Oncology Venture Up-date

Hoersholm, Denmark; November 9th, 2015 - Oncology Venture Sweden AB
(OV:ST) up-dates information about drug candidates in the pipeline.

Irofulven: The screening part of the trial is expected to include its
first patients in Q4 2015. Following the production of Irofulven,
which has already been initiated, first patient treated is expected
in late Q2-Q3 2016. Production of Irofulven has been initiated.

APO010: old drug on stock may be useful in the planned trial of
Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL). This
causes potential large initial savings on production costs. 5 mg of
APO010 from stock has been sold to non-competing undisclosed company
for 176.000 USD.

Furthermore, OV has acquired yet two Drug Response Prediction DRP™
licenses from MPI A/S on two undisclosed promising anticancer
products.

Irofulven

Background: Irofulven is an anticancer drug in-licensed from Lantern
Pharma. The two companies received a grant of 800t USD from
Massachusetts Life Sciences Center to develop Irofulven in prostate
cancer. An Irofulven DRP™, a gene expression data based Irofulven
responsive predictor, has been developed by MPI A/S and in-licensed
into OV.

Irofulven has been studied in 38 clinical trials (19 published)
between 1995 and 2007, in which it has demonstrated promising single
agent activity in a range of indications, including prostate cancer,
ovarian, liver and pancreatic cancer, and clinical activity. For
example, Irofulven demonstrated a 10% response rate in prostate
cancer patients previously treated with docetaxel.

Up-date: A clinical phase 2 trial including a screening process is now
to be initiated in selected patients with castration - and docetaxel
resistant prostate cancer by using the Irofulven DRP™. 150 (possibly
later extended to 600) patients are expected to be screened and 10%
of the patients with the highest likelihood of benefit from Irofulven
will be offered to participate in the trial. The aim is to improve
the response rate to a clinical relevant and approvable level. The
screening part of the trial is expected to include its first patient
in Q4 2015. Following the production of Irofulven which has already
been initiated first patient treated is expected in late Q2-Q3 2016.

APO010 Up-date

License agreement: In October 2015 OV prolonged its license agreement
with Onxeo regarding APO010. The license agreement gives OV global
rights, royalties etc. in line with the previous communicated.

Production of APO010: OV has existing APO010 product that was produced
in 2007 which is still active and stable. Currently OV has an expert
team investigating whether the product can be approved for use in
clinical trials. This will save a substantial amount of money and
allow OV to commence an APO010 trial faster than if OV has to produce
a new batch. If it is possible to use the old batch OV may initiate
the first trial in Q2 2016.

Phase 2 clinical trial: APO010 was previously run in Switzerland at
two sites. Two cohorts of 3 patients will initially in the current
trial be included to establish the recommended phase 2 dose. The
phase 2 trial has been designed to include MM and CLL patients and
hematology experts on two sites in Denmark are interested in
participation in the testing of APO010 in these two blood cancer
diseases. The screening part of the trial is expected to begin as
soon as OV has a green light from its production. In the MM/CLL all
patients have the FAS-receptor. The APO010 is a FAS-ligand drug

and only works when the FAS-receptor is there but this is not enough
and OV use its DRP to find the high likelihood responders. It is
anticipated that 50% of the patients will respond when the
recommended APO010 dose is found. Accordingly the top 50% will be
included in the trial and more than 50 patients will therefore be
screened in order to be able to include 20 - 25 patients in the
trial.

Sales of APO010: OV has in November 2015 sold 5 mg of their current
stock of APO010 for 176.000 USD to an undisclosed company developing
APO010 for a non-competing project which uses APO010 outside the body
i.e. not competing with OVs plans. The product may also be sold in
the future for this purpose if tests pan out as expected.

New drugs in the pipeline

Up-date: Oncology Venture has acquired DRP license to two new
promising anticancer drugs and work and discussions with drug owners
is ongoing to further evaluation of the business potential. For
business reasons the identity of the drugs cannot be revealed. The
details of the license are explained in the OV Memorandum from summer
2015. The price of a DRP™ report is 120.000 DKK.

Oncology Venture has built an expert team of part time oncologists and
hematologist researching the area of promising drugs to support the
US team in Boston and Arizona to find the best products and help
negotiate deals.

For further information concerning Oncology Venture please contact:
Peter Buhl Jensen, CEO
Telephone: +45 21 60 89 22
E-mail: pbj@oncologyventure.com

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development
of anti-cancer drugs via its wholly owned Danish subsidiary Oncology
Venture ApS. Oncology Venture has a license to use Drug Response
Prediction - DRP™ - in order to significantly increase the
probability of success in clinical trials. The business enterprise is
based on "rescuing" anti-cancer drugs whose development has been
interrupted in the clinical development stage. DRP™ has proven its
ability to provide a statistically significant prediction of clinical
outcomes from drug treatment in cancer patients in 26 of the 32
clinical studies that were examined.

The Company uses a model that alters the odds in comparison with
traditional pharmaceutical development. Instead of treating all
patients with a particular type of cancer, patients are screened
first and only those who are most likely to respond to the treatment
will be treated. Via a more well-defined patient group, the risk and
costs are reduced while the development process becomes more
efficient.

-----------------------------------------------------------
http://news.cision.com/oncology-venture/r/oncology-venture-up-date,c9863934
http://mb.cision.com/Main/12685/9863934/442147.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.